SHBG (Extended) Longevity-Medicine Target Ranges: What Optimal Looks Like

What SHBG Actually Measures and Why "Extended" Matters

The extended SHBG panel reports total SHBG in nmol/L alongside calculated free testosterone, calculated bioavailable testosterone, and (at some labs) calculated free estradiol. Measuring SHBG alone without these derived values is clinically incomplete, because a patient with total testosterone of 600 ng/dL and SHBG of 80 nmol/L has far less biologically active androgen than someone with total testosterone of 450 ng/dL and SHBG of 20 nmol/L.

SHBG is a homodimeric glycoprotein synthesized predominantly in the liver. It binds testosterone with roughly threefold higher affinity than estradiol, and albumin-bound hormone is loosely held by comparison. The Vermeulen equation, validated against equilibrium dialysis in a 1999 paper in the Journal of Clinical Endocrinology & Metabolism [1], remains the most widely used method for calculating free testosterone from total testosterone, SHBG, and albumin.

Why the "Extended" Label Is Not Just Marketing

A bare SHBG value tells you nothing about sex-steroid bioavailability without the accompanying totals. Ordering the extended panel in one draw saves a repeat venipuncture and provides the three numbers needed to make a clinical decision about TRT, HRT, or dose adjustment.

Specimen and Timing Considerations

Early-morning blood draw is preferred. Testosterone peaks between 07:00 and 09:00, and SHBG has a modest but real diurnal variation. Fasting for at least eight hours before the draw reduces insulin-mediated suppression of SHBG, producing a cleaner baseline [2]. Oral estrogens and thyroid replacement should be noted because they raise SHBG substantially.

Reference Ranges Versus Longevity-Optimized Target Ranges

Standard laboratory reference ranges are derived from population percentiles. They define what is statistically common, not what is metabolically optimal. The distinction matters for longevity medicine.

How Reference Ranges Are Set

Most U.S. Labs report an SHBG reference range for adult men of approximately 16 to 55 nmol/L and a wide range for women of roughly 17 to 125 nmol/L. These are the central 95th-percentile bands from mixed-age, mixed-metabolic-health cohorts. A 55-year-old man with an SHBG of 16 nmol/L is technically "in range" but sits in a zone strongly associated with insulin resistance and type 2 diabetes.

The Epidemiological Case for a Narrower Longevity Target

The Health Professionals Follow-up Study (N = 1,455 men, follow-up 18 years) found that men in the lowest SHBG quartile (below approximately 28 nmol/L) had more than double the risk of developing type 2 diabetes compared with men in the highest quartile (hazard ratio 2.16, 95% CI 1.26 to 3.70) [3]. In the same direction, the NHANES 1999 to 2004 cross-sectional analysis (N = 1,822 men) showed that SHBG was inversely associated with metabolic syndrome components at every quintile below 30 nmol/L [4].

High SHBG carries its own risks. Data from the Massachusetts Male Aging Study (N = 1,709) showed that men with SHBG above 70 nmol/L had significantly lower free testosterone, more sexual dysfunction, and greater bone turnover markers than men in the 30 to 50 nmol/L band [5].

Combining these data, longevity-medicine practitioners target 30 to 50 nmol/L for most adult men and 40 to 80 nmol/L for pre-menopausal women. Post-menopausal women on systemic HRT may accept 30 to 60 nmol/L, especially when non-oral estrogen is used to avoid the hepatic first-pass SHBG elevation from oral estradiol.

HealthRX Longevity Target Framework for SHBG (Extended)

| Population | Longevity Target (nmol/L) | Primary Concern Below Range | Primary Concern Above Range | |---|---|---|---| | Men 18 to 49 | 30 to 50 | Insulin resistance, low free T | Low free T, bone loss | | Men 50+ | 30 to 55 | Metabolic syndrome | Androgen deficiency | | Women (premenopausal) | 40 to 120 | PCOS, androgen excess | Low free T, libido | | Women (postmenopausal, no HRT) | 30 to 80 | Androgen deficiency |, | | Women (postmenopausal, oral estrogen) | 60 to 130 |, | Very low free T | | Women (postmenopausal, transdermal estrogen) | 30 to 70 | Androgen deficiency | Low free T |

SHBG as a Metabolic Biomarker

SHBG is not a passive carrier. It has independent biological signaling roles through a membrane receptor in certain tissues, and its hepatic synthesis is directly suppressed by insulin. This means SHBG is a sensitive, real-time readout of hepatic insulin sensitivity.

Insulin Resistance and SHBG

Elevated fasting insulin suppresses hepatic SHBG production. A 2010 paper in Diabetes Care (N = 6,427 women from the Nurses' Health Study II) found that each standard-deviation increase in SHBG was associated with a 37% lower odds of incident type 2 diabetes after multivariate adjustment [6]. The relationship appears causal: Mendelian randomization analyses using SHBG-associated SNPs confirm that genetically elevated SHBG reduces T2DM risk, suggesting SHBG is at least partly a mediator rather than just a marker [7].

Practical take: a man presenting with SHBG of 18 nmol/L, normal fasting glucose, and no prior diabetes diagnosis should be screened with a fasting insulin and HOMA-IR. The low SHBG may be the first abnormal value in a developing metabolic syndrome.

Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) suppresses SHBG synthesis independent of BMI. A 2019 meta-analysis in Hepatology (7 studies, N = 16,000+) reported that SHBG was significantly lower in NAFLD patients versus matched controls (weighted mean difference approximately 9 nmol/L) [8]. Correcting fatty liver through dietary change or weight loss raises SHBG before fasting glucose fully normalizes.

Thyroid Hormone

Thyroid hormone is a positive regulator of SHBG gene transcription. Overt hyperthyroidism can push SHBG above 100 nmol/L in men. Subclinical hypothyroidism (TSH 2.5 to 10 mIU/L) suppresses SHBG modestly. Any patient with unexplained SHBG outside the 25 to 75 nmol/L range warrants a TSH check alongside the lipid and metabolic panels.

Interpreting SHBG in the Context of Testosterone Therapy

Testosterone replacement therapy (TRT) lowers SHBG through a negative feedback loop on hepatic production. This is generally favorable up to a point, but excessive suppression below 15 nmol/L leaves little buffering capacity and can accelerate estradiol clearance problems.

Free Testosterone Calculation: Numbers That Matter

Using the Vermeulen equation [1]:

• Man, age 42, total testosterone 520 ng/dL (18.0 nmol/L), SHBG 48 nmol/L, albumin 4.3 g/dL: free testosterone = approximately 8.2 ng/dL (0.28 nmol/L), which is mildly low.
• Same man on testosterone cypionate 100 mg/week IM: total testosterone 850 ng/dL, SHBG drops to 24 nmol/L: free testosterone = approximately 22 ng/dL (0.76 nmol/L), well into the optimal range.

The extended panel captures this shift. Ordering only total testosterone after starting TRT misses the story.

Oral Testosterone and SHBG

Oral testosterone undecanoate (Jatenzo, approved by the FDA in 2019) bypasses hepatic first-pass metabolism via the lymphatic route, producing smaller SHBG changes than oral 17-alpha-alkylated androgens. Still, some hepatic exposure occurs, and SHBG should be rechecked at 6 and 12 weeks after initiation to confirm the expected mild reduction [9].

Anastrozole and SHBG

Anastrozole (1 mg/day), sometimes used off-label in men with high estradiol on TRT, raises SHBG by reducing estrogen-mediated suppression of hepatic SHBG synthesis. A rise from 22 to 38 nmol/L after starting anastrozole can paradoxically lower free testosterone even when total testosterone is unchanged. Monitoring the extended panel at 6 to 8 weeks after any aromatase inhibitor adjustment is standard practice in men's hormone protocols.

Interpreting SHBG in Women on HRT or Hormonal Contraception

SHBG in women is more dynamic than in men and reacts strongly to exogenous estrogen and progestins.

Route of Estrogen Administration

Oral estradiol raises SHBG two- to fourfold through the hepatic first-pass effect. Transdermal estradiol at standard doses (50 to 100 mcg/day patch or equivalent gel) produces little SHBG change. This is clinically significant because a woman transitioning from 1 mg oral estradiol to a 75 mcg estradiol patch may see her SHBG fall from 150 nmol/L to 60 nmol/L, substantially increasing free testosterone and free estradiol at the same nominal total levels [10].

Hormonal Contraception

Combined oral contraceptives (COCs) containing ethinyl estradiol markedly raise SHBG, sometimes to 150 to 200 nmol/L. This reduces free testosterone and may contribute to the persistent low libido and diminished clitoral sensitivity reported by some women. A 2006 study in The Journal of Sexual Medicine (N = 124) found that SHBG remained elevated for up to 6 months after stopping COCs in some women, suggesting a prolonged effect on androgen bioavailability [11].

PCOS and Low SHBG

Polycystic ovary syndrome is the leading cause of SHBG below 30 nmol/L in premenopausal women. Insulin-driven suppression of hepatic SHBG production amplifies the relative androgen excess. SHBG below 30 nmol/L in a woman of reproductive age should prompt evaluation for PCOS with luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone, free androgen index, and fasting insulin.

Cardiovascular and Mortality Risk: What the Prospective Data Show

SHBG's relationship with cardiovascular disease (CVD) is bidirectional and non-linear, which is why a "higher is always better" or "lower is always better" framing is incorrect.

Low SHBG and Cardiovascular Risk in Men

The European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) cohort (N = 11,606 men, median follow-up 12.7 years) found that men in the lowest SHBG quartile (below 26 nmol/L) had a 1.42-fold higher risk of fatal coronary heart disease compared with the middle two quartiles (P<0.01) [12]. This risk was partially but not fully mediated by metabolic syndrome, suggesting independent SHBG effects.

High SHBG, Androgen Deficiency, and Bone Health

Men with SHBG above 70 nmol/L and consequently low free testosterone are at elevated risk for osteoporosis. The Osteoporotic Fractures in Men (MrOS) study (N = 2,447, mean age 73.6) showed that free testosterone below 70 pg/mL (partially driven by high SHBG) predicted incident hip fracture independent of total testosterone [13]. Bone mineral density screening should accompany SHBG values consistently above 60 nmol/L in men over 50.

Women and Cardiovascular Risk

In post-menopausal women, very low SHBG (<30 nmol/L) correlates with higher rates of metabolic syndrome, and data from the Women's Health Initiative Observational Study (N = 2,834) linked low SHBG with greater risk of coronary heart disease [14]. Conversely, very high SHBG from hepatic disease or malnutrition is a marker of general physiological compromise rather than an independent CVD driver.

What Drives SHBG Up or Down: A Practical Clinical Checklist

Understanding what moves SHBG allows clinicians to identify correctable causes before attributing all variation to age or genetics.

Factors That Lower SHBG

• Obesity and visceral adiposity (strongest modifiable driver)
• Hyperinsulinemia and insulin resistance
• Hypothyroidism (even subclinical)
• Anabolic-androgenic steroid use (exogenous androgens suppress hepatic production)
• Glucocorticoid excess or chronic steroid use
• Growth hormone excess (acromegaly)
• Nephrotic syndrome (protein loss lowers carrier proteins)
• Genetic polymorphisms in the SHBG gene (SHBG rs1799941 SNP accounts for 10 to 15% of variance)

Factors That Raise SHBG

• Oral estrogens (oral contraceptives, oral HRT)
• Hyperthyroidism
• Liver cirrhosis (paradoxically, through decreased metabolic clearance)
• Anorexia nervosa and severe caloric restriction
• Aging (SHBG rises roughly 1 to 2% per year after age 40 in men)
• HIV and certain antiretrovirals
• Phenytoin and some other anticonvulsants (induce hepatic SHBG synthesis)

What Lifestyle Interventions Do

Weight loss of 10% body weight raises SHBG by approximately 10 nmol/L in men with metabolic syndrome, based on data from a controlled dietary intervention reported in The American Journal of Clinical Nutrition [15]. Resistance training has a modest independent effect. Time-restricted eating, insofar as it reduces fasting insulin, likely raises SHBG through the insulin-hepatic axis.

How to Use SHBG Data in a Clinical Visit

The extended SHBG panel generates three to four numbers. A structured interpretation approach prevents both under-reaction (treating an abnormal SHBG as a single lab) and over-reaction (changing hormone doses based on SHBG in isolation).

Step 1: Assess the SHBG Value in Its Metabolic Context

Pull fasting insulin, hemoglobin A1c, TSH, and ALT alongside the extended SHBG panel when ordering for the first time. An SHBG of 18 nmol/L in a man with fasting insulin of 22 mIU/L is a metabolic problem. The same value with normal insulin and a testosterone of 200 ng/dL is a different problem requiring different treatment.

Step 2: Calculate the Free Androgen Index if Free Testosterone Is Not Reported

Free androgen index (FAI) = (total testosterone nmol/L / SHBG nmol/L) x 100. In men, an FAI below 30 is generally considered low. In women, an FAI above 5 suggests androgen excess. This is a rough tool. The Vermeulen-calculated free testosterone is more precise when albumin is available.

Step 3: Recheck at the Right Interval

After initiating or adjusting TRT or HRT, recheck the extended SHBG panel at 6 weeks (TRT) or 8 to 12 weeks (HRT). Steady-state for exogenous testosterone cypionate is approximately 4 to 5 injection cycles; SHBG stabilizes within 6 to 8 weeks of a stable dose.

Step 4: Do Not Treat SHBG in Isolation

The Endocrine Society's 2018 guideline on testosterone therapy in men states: "We recommend against making the diagnosis of androgen deficiency based solely on total testosterone concentration without assessment of free or bioavailable testosterone when SHBG is suspected to be abnormal" [16]. The extended panel exists precisely to operationalize this recommendation.

Monitoring Cadence for Longevity-Medicine Patients

Patients enrolled in a longevity or precision-medicine program need SHBG measured more frequently than annual physicals typically allow. Below is a practical schedule based on clinical status.

For patients off all exogenous hormones and metabolically stable: every 12 months alongside a full hormone panel.

For patients on TRT: at baseline, 6 weeks, 3 months, then every 6 months once stable. Any change in dose or delivery method triggers a 6-week recheck.

For women on HRT: at baseline, 8 to 12 weeks after initiation or route change, then every 6 to 12 months.

For patients actively losing weight or reversing insulin resistance: every 6 months, since SHBG tracks the metabolic improvement and can guide dose adjustments in patients already on hormone therapy.